Search Results - Azar Shahraz

Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ” by Azar Shahraz, Jincheng Yang, Diansong Zhou, Karthick Vishwanathan, Dana Ghiorghiu, Yuri Rukazenkov, Aarti Sawant‐Basak

Get full text

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC by Jincheng Yang, Damilola Olabode, Aarti Sawant‐Basak, Richard Baldry, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Diansong Zhou, Azar Shahraz

Get full text

A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection by Azar Shahraz, Mark Penney, Juliana Candido, Grace Opoku‐Ansah, Melanie Neubauer, Jim Eyles, Oluwaseun Ojo, Nelson Liu, Nadia M. Luheshi, Alex Phipps, Karthick Vishwanathan

Get full text